Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy

Short Hairpin RNA-Mediated Fibronectin Knockdown Delays Tumor Growth in a Mouse Glioma Model

(2015) Sadhak Sengupta et al.   NEOPLASIA

Recent developments on immunotherapy for brain cancer

(2012) Derek A Wainwright et al.   EXPERT OPINION ON EMERGING DRUGS

Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells

(2012) Caroline Happold et al.   JOURNAL OF NEUROCHEMISTRY

A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy

(2011) Guan Jiang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Monoclonal antibody blockade of IL-2 receptor   during lymphopenia selectively depletes regulatory T cells in mice and humans

(2011) D. A. Mitchell et al.   BLOOD

Chemoresistance to Temozolomide in Human Glioma Cell Line U251 is Associated with Increased Activity of O 6-methylguanine-DNA Methyltransferase and Can be Overcome by Metronomic Temozolomide Regimen

(2011) Qiang Pan et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy

(2011) Camilo E. Fadul et al.   JOURNAL OF IMMUNOTHERAPY

Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme

(2011) C. E. Fadul et al.   NEURO-ONCOLOGY

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide

(2010) K A van Nifterik et al.   BRITISH JOURNAL OF CANCER

Dose-dense temozolomide regimens

(2010) Bart Neyns et al.   CANCER

Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen

(2010) Masasuke Ohno et al.   CANCER SCIENCE

Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks

(2010) J. N. Sarkaria et al.   CLINICAL CANCER RESEARCH

Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors

(2010) Vita Ridola et al.   JOURNAL OF NEURO-ONCOLOGY

Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy

(2010) Xinmei Zhu et al.   JOURNAL OF NEURO-ONCOLOGY

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

(2010) J. H. Sampson et al.   NEURO-ONCOLOGY

Low Peripheral Lymphocyte Count Before Focal Radiotherapy Plus Concomitant Temozolomide Predicts Severe Lymphopenia During Malignant Glioma Treatment

(2010) Eiichi ISHIKAWA et al.   NEUROLOGIA MEDICO-CHIRURGICA

Acquired Resistance to Temozolomide in Glioma Cell Lines: Molecular Mechanisms and Potential Translational Applications

(2010) Jihong Zhang et al.   ONCOLOGY

The Presence of IL-17A and T Helper 17 Cells in Experimental Mouse Brain Tumors and Human Glioma

(2010) Derek A. Wainwright et al.   PLoS One

MGMT promoter methylation in malignant gliomas

(2010) Markus J. Riemenschneider et al.   Targeted Oncology

Engineered drug-resistant immunocompetent cells enhance tumor cell killing during a chemotherapy challenge

(2009) Anindya Dasgupta et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model

(2009) Claire Banissi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immunological Factors Relating to the Antitumor Effect of Temozolomide Chemoimmunotherapy in a Murine Glioma Model

(2009) T.-G. Kim et al.   Clinical and Vaccine Immunology

The safety of temozolomide in the treatment of malignancies

(2009) Van Anh Trinh et al.   Expert Opinion On Drug Safety

Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O6-methylguanine-DNA methyltransferaseP140K

(2009) P Maier et al.   GENE THERAPY

Genetically engineered T cells to target EGFRvIII expressing glioblastoma

(2009) Szofia S. Bullain et al.   JOURNAL OF NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Challenges in Clinical Design of Immunotherapy Trials for Malignant Glioma

(2009) Cleo E. Rolle et al.   NEUROSURGERY CLINICS OF NORTH AMERICA

The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity

(2008) Maya Remington et al.   NEURO-ONCOLOGY

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts

(2008) Gaspar J. Kitange et al.   NEURO-ONCOLOGY

Mechanisms of Disease: temozolomide and glioblastoma—look to the future

(2008) Maciej M Mrugala et al.   Nature clinical practice. Oncology

Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study

(2007) Amy B. Heimberger et al.   NEURO-ONCOLOGY